Rare diseases, orphan drugs and their regulation: questions and misconceptions
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Sustained advocacy efforts driven by patients' organizations to make rare diseases a health priority have led to regulatory and economic incentives for industry to develop drugs for these diseases, known as orphan drugs. These incentives, enacted in regulations first introduced in the United States in 1983 and later in Japan, Europe and elsewhere, have resulted in substantial improvements in the treatment for patients with a range of rare diseases. However, the advent of orphan drug development has also triggered several questions, from the definition of rarity to the pricing of orphan drugs and their impact on health-care systems. This article provides an industry perspective on some of the common questions and misconceptions related to orphan drug development and its regulation, with the aim of facilitating future progress in the field.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Standard randomized placebo-controlled clinical trials in hundreds of patients will therefore be difficult to achieve for ASD, and specific clinical trials designed for rare diseases need to be devised 90 .”
From Progress toward treatments for synaptic defects in autism (2013) · cites this paper as [90]
Citations
Cites
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“, although others claim that this number could be as high as 50”
BackgroundRelative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers
Eichler, H.-G., Bloechl-Daum, B., Abadie, E., Barnett, D., König, F., & Pearson, S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3079 · Cited by 174
The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?
Wellman-Labadie, O., & Zhou, Y. (2010) · Health Policy · doi:10.1016/j.healthpol.2009.12.001 · Cited by 166
Adopting Orphan Drugs — Two Dozen Years of Treating Rare Diseases
Haffner, M. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmp058317 · Cited by 162
Orphan drug development is not taking off
Joppi, R., Bertelè, V., & Garattini, S. K. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03369.x · Cited by 64
Orphan drug policies: implications for the United States, Canada, and developing countries.
Cheung, R. Y., Cohen, J. C., & Illingworth, P. (2004) · PubMed · Cited by 49
From research on rare diseases to new orphan drug development
Heemstra, H. (2010) · Utrecht University Repository (Utrecht University) · Cited by 3
Research works printed but not linked: 5
- La Revue Prescire – Enquête. Médicaments pour les maladies rares: bilan contrasté en Europe — Synthèse élaborée collectivement par la Rédaction. La Revue Prescire 26, 781 (2006) (in French).
- Hirschhorn, R. & Reuser A. J. J. in The Metabolic & Molecular Bases of Inherited Diseases 8th edn (eds Scriver C. R. et al.) 3395 (McGraw-Hill, New York, 2001).
- Genzyme Corporation. Genzyme annual report 2004. (Genzyme, Cambridge, Massachusetts, 2004).
- The European Platform for Patients' Organisations, Science and Industry. The 8th workshop on partnering for rare disease therapy development: the reality of orphan medicines. The Platform for Patients' Organisations, Science and Industry website [ online ], (2007).
- Commission of the European Communities. Guideline on aspects of the application of Article 8(2) of Regulation (EC) No 141/2000: review of the period of market exclusivity of orphan medicinal products. The European Commission website [ online ], (2008).
Cited by
Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial
Coelho, T., Maia, L. F., Martins da Silva, A., Waddington Cruz, M., Planté-Bordeneuve, V., Lozeron, P., Suhr, O. B., Campistol, J. M., Conceição, I. M., Schmidt, H. H.-J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661eb1 · Cited by 816
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
Self-citationGammie, T., Lu, C. Y., & Babar, Z. U.-D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140002 · Cited by 277
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Pricing and reimbursement of orphan drugs: the need for more transparency
Simoens, S. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-42 · Cited by 260
Metadata
- Authors
- Tambuyzer, E.
- Corresponding author
- Tambuyzer, Erik
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-11-09
- Volume
- 9
- Issue
- 12
- Pages
- 921-929
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2019375534
- Cited by
- 182
- References
- 7
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 12 · 2023: 12 · 2022: 13 · 2021: 16 · 2020: 7 · 2019: 11 · 2018: 6 · 2017: 13 · 2016: 10 · 2015: 7 · 2014: 15 · 2013: 15 · 2012: 17
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- rare diseases, orphan drugs, orphan drug regulation, regulatory incentives, drug pricing, health care system impact, patient advocacy, pharmaceutical industry perspective
- MeSH terms
- Humans, Orphan Drug Production, United States, United States Food and Drug Administration, Drug Approval, Rare Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.